Y Intercept Hong Kong Ltd Increases Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)

Y Intercept Hong Kong Ltd raised its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 3.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,206 shares of the company’s stock after purchasing an additional 845 shares during the quarter. Y Intercept Hong Kong Ltd owned approximately 0.09% of Castle Biosciences worth $690,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its stake in shares of Castle Biosciences by 2.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after buying an additional 40,377 shares in the last quarter. Bellevue Group AG raised its holdings in Castle Biosciences by 3.7% during the 3rd quarter. Bellevue Group AG now owns 1,262,030 shares of the company’s stock valued at $35,993,000 after acquiring an additional 44,929 shares during the period. Portolan Capital Management LLC lifted its position in shares of Castle Biosciences by 3.7% during the third quarter. Portolan Capital Management LLC now owns 1,255,628 shares of the company’s stock worth $35,811,000 after acquiring an additional 44,676 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Castle Biosciences by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company’s stock worth $17,631,000 after acquiring an additional 60,675 shares during the period. Finally, State Street Corp grew its position in shares of Castle Biosciences by 9.8% in the third quarter. State Street Corp now owns 680,001 shares of the company’s stock valued at $19,394,000 after purchasing an additional 60,924 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $28.87 on Friday. The company has a market capitalization of $808.56 million, a P/E ratio of 144.35 and a beta of 0.92. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. Castle Biosciences, Inc. has a 52-week low of $16.97 and a 52-week high of $35.84. The company has a fifty day moving average of $31.30 and a 200-day moving average of $27.10.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.14. The firm had revenue of $85.78 million for the quarter, compared to analyst estimates of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same period in the prior year, the company earned ($0.26) EPS. As a group, equities research analysts predict that Castle Biosciences, Inc. will post 0.34 EPS for the current fiscal year.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Tobin W. Juvenal sold 3,507 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the sale, the insider now directly owns 54,178 shares in the company, valued at $1,926,569.68. This represents a 6.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Derek J. Maetzold sold 986 shares of Castle Biosciences stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $28.73, for a total value of $28,327.78. Following the completion of the transaction, the insider now owns 94,622 shares in the company, valued at approximately $2,718,490.06. This represents a 1.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,185 shares of company stock worth $814,495 over the last ninety days. Insiders own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CSTL. BTIG Research lifted their target price on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday, October 14th. Scotiabank boosted their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 6th. Lake Street Capital increased their target price on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group boosted their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Finally, KeyCorp upped their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Castle Biosciences has a consensus rating of “Buy” and an average price target of $37.88.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.